The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | John Gribben’s ASH 2019 CLL and lymphoma highlights
John Gribben, MD, DSc, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, gives a round up of lymphoma and chronic lymphocytic leukemia (CLL) research that has been presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, including longer follow-up and novel agents in early development. While majority of the updates may not be changing the therapeutic landscape completely, they none-the-less are crucial for optimizing treatment.
